2022-06-03

Neurotransmission-Related Gene Expression in the Frontal Pole (Brodmann Area 10) is Altered in Subjects with Bipolar Disorder and Schizophrenia

Adriana Medina M.D., Ph.D.*[1], Megan Hastings Hagenauer Ph.D.*[1], David M. Krolewski Ph.D*.[1], Evan Hughes M.S.[1], Liam Cannon Thew Forrester[1,] David M. Walsh Psy.D.[2], Maria Waselus Ph.D.[1], Evelyn Richardson[1], Cortney A. Turner Ph.D.[1], Adolfo Sequeira Ph.D.[2], Preston Cartagena Psy.D. [2], Robert C. Thompson Ph.D. [1], Marquis Vawter Ph.D.[2], Blynn Bunney Ph.D.[2,] Richard M. Myers Ph.D.[3], Jack D. Barchas M.D.[4], Francis Lee M.D., Ph.D.[4], Alan F. Schatzberg M.D.[5], William E. Bunney M.D.[2], Huda Akil Ph.D.[1], Stanley J. Watson M.D., Ph.D.[1]

1 Michigan Neuroscience Institute. University of Michigan, Ann Arbor, MI, United States America,
2 University of California-Irvine, Irvine, CA, United States of America,
3 HudsonAlpha Institute for Biotechnology, Huntsville,
AL, United States of America,
4 Cornell University, New York, NY, United States of America,
5 Stanford University, Palo Alto, CA, United States of America

*Shared first authorship

Correspondence:

Dr. Megan Hagenauer
Michigan Neuroscience Institute
University of Michigan
205 Zina Pitcher Pl.
Ann Arbor, MI, 48109, USA
hagenaue@umich.edu
Phone: 734-709-7204

Abstract

Background: Broadmann Area 10 (BA10) is the largest cytoarchitectonic region of the human cortex and perhaps the most evolutionarily advanced, yet it remains poorly understood, in part due to the complexity of its integrative functions. Bipolar disorder (BP) and schizophrenia (SCHIZ) are two disorders that share symptomatology and genetic risk. The average onset of BP and SCHIZ coincides with the adolescent pruning of BA10 grey matter, suggesting a potential role for BA10 dysfunction in the disorders. In this study, we investigated the role of neurotransmission-related gene expression in BA10 in BP and SCHIZ.

Methods: We performed qPCR to measure the expression of 115 neurotransmission-related targets in control, BP, and SCHIZ post-mortem samples (n=72). We chose this method for its high sensitivity to detect low-level expression. We then bolstered our findings by performing a meta-analysis of publicly-released BA10 microarray data (n=101) and identified sources of convergence with our qPCR results. To improve our interpretation of diagnosis effects, we compiled an unusually large database of clinical metadata for our qPCR samples. We used this data to explore the relationship between BA10 gene expression, therapeutics, substances of abuse, and symptom profiles, and validated these exploratory findings with publicly-available datasets.

Results: Using these convergent sources of evidence, we identified 20 neurotransmission-related genes that were differentially expressed in BP and SCHIZ in BA10. These results include a large down-regulation in BP and SCHIZ of two important therapeutic targets with low-levels of expression, HTR2B and DRD4, as well as other findings related to dopaminergic, GABA-ergic and astrocytic function. We also found evidence that therapeutics may produce differential expression that opposes the effects of diagnosis. In contrast, substances of abuse may be associated with similar effects on BA10 gene expression as BP and SCHIZ, potentially amplifying diagnosis-related dysregulation.

Introduction

The frontal pole of the human brain (Broadman area 10, BA10), is the largest cytoarchitectonic region of the cortex (1) and yet it is also the least understood. BA10 in humans differs greatly from its counterpart in other primates and model organisms. Relative to other apes, human BA10 occupies twice the proportion of the total cortical extension (2–4). And while the cytoarchitecture of most cortical areas shows only modest differences between primates, the frontal pole is an exception. BA10 has much lower cellular density and greater intercellular distance in humans when compared to other species (2,4,5), and a higher number of dendritic spines per cell compared to adjoining areas (5). This suggests that BA10 has high levels of input integration that could surpass that of adjacent cortical fields.

In general, the role of BA10 has been hard to pinpoint because of the complex nature of its associated functions. Patients suffering from substantial losses of BA10 grey matter can perform adequately on most neuropsychological tests but are frequently incapable of maintaining employment or performing daily tasks, such as cooking. The main deficiency appears to be an inability to construct a coherent series of steps toward completion (1), due to deficits in prospective memory (remembering intention) and time estimation. BA10 also allows for the integration of internally and externally obtained cognition (1). This concept is particularly important for the study of psychotic disorders, with symptoms including delusions, hallucinations, and disorganized speech. Furthermore, there is a large decrease in BA10 grey matter during adolescence and young adulthood. This developmental pruning period coincides with the average age of onset of Bipolar Disorder (BP) and Schizophrenia (SCHIZ). It is notable that the adolescent decrease in BA10 grey matter does not occur normally in SCHIZ (6). This makes BA10 an attractive target for a better understanding of psychotic disorders.

For the present study, we investigated the role of BA10 in BP and SCHIZ, as both disorders share symptomatology and genetic risk (7,8). We focused on neurotransmission-related gene expression due to its relevance to both disease etiology and the design of therapeutics (9–11). We chose the highly-sensitive method of qPCR, allowing us to both confirm and expand on previous studies tackling the topic with gene expression profiling (12–16). We then augmented our findings with an in-depth examination of accompanying clinical characteristics. Our results provide compelling insight into the physiology of both disorders.

Results

To evaluate the effects of BP and SCHIZ on neurotransmission-related gene expression in BA10 using highly sensitive methodology, we ran all samples in duplicate on two custom sets of Taqman microfluidic qPCR cards from Applied Biosystems. These cards were preloaded with a complete list of targets for the main neurotransmitter systems in the frontal cortex: glutamate, GABA, dopamine, and serotonin (17), including receptors, transporters, metabolic enzymes, and other associated molecules. The cards were further customized to include several well-known markers for interneuron subtypes (SST, PVALB, CALB1) and astrocytes (AQP4, GJA1, GFAP, KCNJ10, S100B) to enhance the interpretation of neurotransmission-related data. We then performed a meta-analysis of previous BA10 microarray studies (12,13) and used the convergence between our qPCR and microarray results to identify additional differentially-expressed neurotransmission-related genes.

To explore the function of these differentially-expressed genes, we compared our findings to previous transcriptional profiling studies of neighboring cortical areas, and also evaluated the similarity of differential expression associated with the two disorders. We then leveraged the unusually large database of metadata associated with our qPCR samples to

explore the relationship between gene expression and clinical characteristics and compared these exploratory findings to results from publicly-available datasets.

A summary of the main findings is presented below. Comprehensive details are in the Supplement, including full sample metadata (**Tables S1 & S3**) and complete statistical reporting for the full concatenated qPCR and microarray results (**Tables S2, S4, S6-7).**

qPCR Results

Balanced Design: Tissue was collected from 72 subjects. Three subjects were later excluded due to poor RNA quality metrics, leaving n=69 (CTRL: n=26, BP: n=21, SCHIZ: n=22). Subjects were predominantly male, although a quarter of the BP group was female (CTRL: n=25M/1F, BP: n=15M/6F, SCHIZ: n=21M/1F, Fisher's Exact Test: p=0.0174). The diagnosis groups were otherwise balanced in regard to critical biological and technical variables (**Tables S1 & S3, Figs S2 & S5,** p>0.10: age, brain pH, post-mortem interval (PMI), tissue block weight, the concentration, purity (260/280, 260/230), and RNA integrity (RNA integrity number (RIN), 28S/18S) of purified RNA). All subjects had experienced a fast death (agonal factor score=0).

Effect of Diagnosis: We characterized the effect of diagnosis on the expression of 111 neurotransmission-related target genes within two qPCR experiments ("GABA-GLU" and "DA-5HT"), while controlling for sources of biological and technical noise (pH, PMI, age, gender, RIN, RNA concentration, Card). As expected, qPCR accurately measured the expression of target genes with extremely low levels of expression (quantification cycles (Cq) between 27-34.6) without a decrease in accuracy (**Fig S14, Table S2**). This allowed us to accurately characterize the relationship between diagnosis and the expression of neurotransmission-related genes that were not reliably quantifiable within previous microarray and RNA-Seq studies (**Fig S14**).

Indeed, two of our strongest findings were monoamine receptor genes with very low levels of cortical expression: 5-Hydroxytryptamine Receptor 2B (HTR2B, average Cq: 31.8) and Dopamine Receptor D4 (DRD4, average Cq: 33.6). Both of these genes showed a relationship with diagnosis that survived false discovery rate correction (FDR<0.10) due to decreased expression in both BP and SCHIZ (**Fig 1,** *DRD4: p*=0.00196, FDR=0.0495, *post-hoc: BP:* Log2 Fold Change (Log2FC)=-0.466, *p*=0.00510; *SCHIZ:* Log2FC=-0.347, *p*=0.0244; *HTR2B: p*=0.000312, FDR=0.0173, *post-hoc: BP:* Log2FC=-0.681, *p*=0.0270; *SCHIZ:* Log2FC=-0.980, *p*=0.000903). Notably, the size of the effect of SCHIZ on HTR2B was strikingly large - almost a full halving of normal expression levels.

Similar to previous studies, we found that somatostatin (SST) showed a relationship with diagnosis, with lower expression in BP and SCHIZ (**Fig 1,** SST: *p*=0.00223, FDR=0.0495, *post-hoc: BP:* Log2FC=-0.308, *p*=0.0935*trend*; *SCHIZ:* Log2FC=-0.467, *p*=0.00689). Three other genes were related to diagnosis due to elevated expression in both diagnosis groups: 4-aminobutyrate aminotransferase (ABAT), Gephyrin (GPHN), and Mitogen-Activated Protein Kinase 1 (MAPK1) (**Fig 1;** *ABAT: p*=0.00166, FDR=0.0495; *post-hoc: BP:* Log2FC=0.157, *p*=0.00550; *SCHIZ:* Log2FC=0.083, *p*=0.0993*trend*; *GPHN: p*=0.000283, FDR=0.0173, *post-hoc: BP:* Log2FC=0.156, *p*=0.00256; *SCHIZ:* Log2FC=0.101, *p*=0.0295; *MAPK1: p*=0.00372, FDR=0.0688, *post-hoc: BP:* Log2FC=0.135, *p*=0.00113; *SCHIZ:* Log2FC=0.0869, *p*=0.0730*trend*).

Effect of Diagnosis (FDR<0.10):

Figure 1. Six target genes showed a relationship with diagnosis that survived false discovery rate correction (FDR<0.10) in our qPCR experiment. *Boxplots illustrate the distribution of -ΔΔCq values (log2 fold change (Log2FC), with the average for the CTRL group set as 0) for each sample within each diagnosis group (boxes=first quartile, median, and third quartile, whiskers=range and/or 1.5x the interquartile range if there are outlying data points). Note that each datapoint represents an individual replicate without the additional correction for confounding biological or technical variation provided by our statistical model.* ***A)*** *5-Hydroxytryptamine Receptor 2B (HTR2B) showed an effect of Diagnosis (p=0.000312, FDR=0.0173), with a decrease in both Bipolar Disorder (BP, p=0.0270) and Schizophrenia (SCHIZ, p=0.000903).* ***B)*** *Dopamine Receptor D4 (DRD4) showed an effect of Diagnosis (p=0.00196, FDR=0.0495), with a decrease in both BP (p=0.00510) and SCHIZ (p=0.0244).* ***C)*** *Somatostatin (SST) showed an effect of Diagnosis (p=0.00223, FDR=0.0495), with a trend towards a decrease in BP (p=0.0935) and a decrease in SCHIZ (p=0.00689)****, D)*** *4-aminobutyrate aminotransferase (ABAT) showed an effect of Diagnosis (p=0.00166, FDR=0.0495), with elevation in BP (p=0.00550) and a trend towards elevation in SCHIZ (p=0.0993).* ***E)*** *Gephyrin (GPHN) showed an effect of Diagnosis (p=0.000283, FDR=0.0173), with elevation in BP (p=0.00256) and SCHIZ (p=0.0295),* ***F)*** *Mitogen-Activated Protein Kinase 1 (MAPK1) showed an effect of Diagnosis (p=0.00372, FDR=0.0688), with elevation in BP (p=0.00113) and a trend towards elevation in SCHIZ (p=0.0730).*

Similarity to Diagnosis Effects in Previous BA10 Microarray Studies:

We compared our qPCR results to the published results from previous BA10 microarray studies of BP and SCHIZ (12–16) (**Table S5**). To increase consistency, we re-annotated and re-analyzed the data from the two studies with publicly-released data (12,13), and performed a meta-analysis of the SCHIZ effects (Log2FC) in the re-analyzed data.

In general, despite the noise in the microarray data and the lack of sensitivity for low-level expression (**Fig S14**, *e.g.,* HTR2B, DRD4), we observed a similar direction of effect in the BA10 microarray datasets for top differentially expressed genes from our qPCR study (SST, ABAT, MAPK1, GPHN). We also observed a weak positive correlation between our full qPCR results and the re-analyzed BA10 microarray results (**Fig 2, Fig S15**, *qPCR vs. Iwamoto: SCHIZ:* R=0.24, p=0.0179; *BP:* R=0.15, p=0.151: *qPCR vs. Maycox: SCHIZ:* R=0.09, p=0.338*not sig*; *qPCR vs. Meta-analysis: SCHIZ:* R=0.24, p=0.0175). Amongst these results, we identified three additional genes that had nominally significant differential expression (p<0.05) in both the qPCR study and BA10 microarray data as well as a consistent direction of effect (GRM5, NSF, SNCA, **Fig 3**). Our meta-analysis also identified six differentially expressed genes (FDR<0.10) that were not included as qPCR targets: a downregulation of TUBB7P, TIE1, HSD17B8, and URM1 and upregulation of CACYBP and GIT2 with SCHIZ (**Fig S17, Table S6**).

Figure 2. Our qPCR experiment replicated many diagnosis effects observed in the frontal cortex by meta-analyses of less sensitive transcriptional profiling methods (microarray, RNA-Seq). *In addition to detecting novel diagnosis effects in low-level expressed genes (HTR2B, DRD4), our qPCR experiment was able to detect diagnosis effects that were observed in the frontal cortex within our current meta-analysis of previous BA10 microarray studies and in*

*a previously-published meta-analysis of RNA-Seq studies of neighboring frontal cortex. **A)** To provide a more robust comparison, we re-annotated and re-analyzed two publicly-available microarray datasets from BA10 (12,13) and then performed a meta-analysis to identify the differential expression associated with SCHIZ. A scatterplot is shown illustrating the positive correlation (R=0.243, p=0.0175) between this meta-analysis gene expression signature (Log2FC) and the differential expression associated with SCHIZ in our qPCR experiment (Log2FC) for all genes that were present in both datasets (n=95). The color of the datapoints signifies whether a gene showed a nominally significant effect of diagnosis in the microarray meta-analysis results (black: p<0.05, grey: p>0.05). **B)** A scatterplot illustrating the positive correlation (R=0.607, p=6.604e-11) between the differential expression associated with SCHIZ (Log2FC) identified in a very large (n=384: 203 CTRL, 181 SCHIZ) meta-analysis of RNA-Seq data from frontal cortical tissue (18) and the differential expression associated with SCHIZ in our qPCR experiment (Log2FC) for all genes that were present in both datasets (95 genes). The color of the datapoints signifies whether a gene showed a nominally significant effect of diagnosis in the RNA-Seq meta-analysis results (black: p<0.05, grey: p>0.05). **C)** A scatterplot illustrating the positive correlation (R=0.490, p=4.61e-07) between the differential expression associated with BP (Log2FC) identified in a very large (n=171: 101 CTRL, 70 BP) meta-analysis of RNA-Seq data from frontal cortical tissue (18) and the differential expression associated with BP in our qPCR experiment (Log2FC) for all genes that were present in both datasets (95 genes). The color of the datapoints signifies whether a gene showed a nominally significant effect of diagnosis in the RNA-Seq meta-analysis results (black: p<0.05, grey: p>0.05). Datapoints are labeled with official gene symbols for genes that show particularly large Log2FC in both datasets.*

Similarity to Diagnosis Effects in Neighboring Cortical Regions:

We observed a strong positive correlation between the diagnosis effects identified in our qPCR study and those previously observed in the dorsolateral prefrontal cortex (DLPFC) and neighboring frontal cortex in a large meta-analysis of RNA-Seq studies (**Fig 2**, Log2FC for 95 genes (18): SCHIZ: R=0.61, p=6.604e-11, BP: R=0.49, p=4.61e-07). As RNA-Seq still lacked sensitivity for measuring low level expression (**Fig S14**), the strength of this correlation most likely reflected the statistical power of the RNA-Seq meta-analysis (*SCHIZ vs. CTRL: n=384; BP vs. CTRL:* n=171). A comparison of our qPCR findings to smaller DLPFC microarray studies ((19,20), re-analyzed in (21)), produced weaker positive correlations (all p>0.10: **Fig 2**).

Altogether, there were 13 neurotransmission-related genes that showed at least nominally-significant (p<0.05) diagnosis-related effects in BA10 within either our qPCR experiment or in the re-analyzed BA10 microarray data, as well as similar effects (p<0.05, consistent direction) within the neighboring frontal cortex (**Fig 3**).

Gene Symbol	BP: Log2FC				SCHIZ: Log2FC						
	BA10		DLPFC/FC		BA10				DLPFC/FC		
	Pritzker_qPCR	Iwamoto_Microarray	Gandal_RNA-Seq_MetaAnalysis	Lanz_Microarray	Pritzker_qPCR	Microarray_MetaAnalysis	Iwamoto_Microarray	Maycox_Microarray	Gandal_RNA-Seq_MetaAnalysis	Lanz_Microarray	Narayan_Microarray
HTR2B	**-0.68**	0.00	NA	-0.08	**-0.98**	-0.05	-0.07	-0.06	NA	**-0.12**	0.04
SST	-0.31	-0.38	**_-0.35_**	-0.32	**-0.47**	-0.22	**-0.55**	0.10	-0.23	-0.16	**-0.47**
DRD4	**-0.47**	-0.03	NA	0.05	**-0.35**	-0.04	0.00	0.02	NA	0.03	-0.01
BDNF	-0.24	-0.08	**-0.18**	0.00	**-0.35**	-0.10	-0.09	-0.09	**-0.28**	-0.09	-0.20
DRD2	-0.14	0.02	NA	**-0.10**	**-0.25**	-0.04	0.03	-0.04	NA	-0.01	-0.01
DRD3	-0.12	-0.07	NA	**-0.09**	**-0.31**	-0.04	0.00	-0.06	NA	-0.03	0.02
HOMER1	-0.03	-0.09	**_-0.14_**	-0.05	**-0.13**	0.04	0.03	-0.01	-0.21	-0.08	-0.10
SLC6A12	-0.01	**-0.29**	-0.09	-0.05	-0.07	**-0.16**	-0.17	-0.11	**_-0.09_**	-0.14	-0.08
COMT	0.05	-0.12	0.03	0.00	0.07	**-0.13**	**-0.19**	**-0.13**	0.01	0.00	**0.10**
SLC6A11	0.19	0.04	-0.02	-0.01	0.00	**-0.05**	-0.02	**-0.08**	**_-0.10_**	-0.07	0.08
GABRB1	0.07	0.06	0.04	**0.09**	**0.12**	0.07	0.13	0.01	0.00	**0.14**	0.12
GRM5	**0.16**	0.04	0.00	0.05	0.00	**0.07**	0.05	**0.12**	0.01	0.08	0.02
CALB1	0.12	0.03	-0.05	0.06	0.02	**0.50**	**0.34**	**0.67**	**_0.13_**	**0.28**	0.10
ABAT	**0.16**	0.02	-0.03	**0.07**	0.08	0.06	0.04	0.04	**_-0.05_**	0.07	0.01
MAPK1	**0.14**	0.06	0.00	-0.02	0.09	0.06	-0.05	0.08	**-0.04**	-0.03	-0.04
NSF	**0.11**	-0.04	**-0.07**	-0.05	**0.10**	0.19	0.08	**0.33**	-0.04	-0.03	**-0.15**
SNCA	0.10	0.00	-0.06	-0.05	**0.10**	0.11	0.02	**0.28**	-0.05	-0.05	**-0.16**
GPHN	**0.16**		-0.03	0.01	**0.10**			0.10	-0.02	0.00	-0.11
MAOB	0.14	0.03	0.03	0.04	**0.22**	0.11	0.16	-0.01	**_0.12_**	**0.10**	0.13
GFAP	0.26	0.16	0.08	0.14	**0.44**	0.00	-0.03	-0.07	**0.13**	0.09	0.17

Down-Regulated

Diagnosis Log2FC

Up-Regulated

Bold & Underline: FDR<0.10, **Bold**=p<0.05

Figure 3. A table overviewing the most supported effects of diagnosis on neurotransmission-related gene expression in BA10. *The table illustrates the effects of diagnosis (Log2FC, left: BP, right, SCHIZ) on neurotransmission-related gene expression as identified in our BA10 qPCR experiment (column highlighted in grey), our re-analysis of two BA10 microarray datasets (Iwamoto et al. and Maycox et al. (12,13)), and our meta-analysis of the SCHIZ results from the two BA10 microarray datasets. These results often paralleled results from neighboring DLPFC/frontal cortex: a large meta-analysis of RNA-Seq data from the DLPFC/frontal cortex (Gandal et al. (18)) and results from two smaller microarray datasets from the DLPFC with grey matter-focused dissections (Lanz et al. and Narayan et al. (19,20) as re-analyzed by (21)). Note that we did not include the results from the large Gandal et al. (18) meta-analysis of microarray data because it was from a more broadly defined anatomical region ("cortex") and included data from the Maycox et al. (13), Lanz et al. (19) and Narayan et al. (20) studies already in the table. To be included in the table a gene needed to show strong evidence of differential expression in BA10: either FDR<0.10 in our qPCR experiment (gene symbol with grey shading) or p<0.05 (Log2FC in bold text) and consistent direction of effect in two independent datasets from BA10 or in a BA10 dataset and DLPFC/frontal cortex dataset.*

Throughout the table, red is used to indicate upregulation and blue is used to indicate downregulation.

Similarity of Neurotransmission-Related Differential Expression Across Diagnosis Categories

BP and SCHIZ showed strikingly similar effects on gene expression when examining results across all 111 target genes in our qPCR analysis (**Fig 4,** BP vs. SCHIZ: R=0.82, *p*<2e-16). We also observed a strong correlation between the effects of BP and SCHIZ on neurotransmission-related gene expression within the re-analyzed BA10 microarray data (*Iwamoto:* R=0.43, p=1.32e-05) and within results from previous frontal cortical studies (RNA-Seq meta-analysis (18): R=0.80, p<2e-16; Microarray (19): R=0.82, p<2.2e-16).

Alone, the strong correlation between the effects of different diagnoses within individual datasets is difficult to interpret, because diagnosis groups are typically compared to a shared control group. However, when comparing across datasets, these correlations become more compelling. For example, the correlation between the effects of SCHIZ within our qPCR dataset and the effects of BP within the RNA-Seq meta-analysis (18) was almost as large as comparing the effects of SCHIZ within our qPCR dataset to the effects of SCHIZ within the RNA-Seq meta-analysis (*SCHIZ vs. BP:* R=0.57, p=2.39e-09). A similarly strong correlation was observed when comparing the effects of BP in our qPCR study to the effects of SCHIZ in the RNA-Seq meta-analysis (*BP vs. SCHIZ:* R=0.46, p=3.39e-06).

These results suggest that the differential expression associated with BP and SCHIZ in BA10 may reflect symptoms, risk factors, or experiences common to both disorders.

Figure 4. Cross-Diagnosis Comparison: BP and SCHIZ have similar differential expression in BA10 and neighboring cortex. A. *A scatterplot illustrating the correlation between the Log2FC for BP vs. SCHIZ for the 111 target genes included in our two qPCR datasets. In general, there is a strong positive correlation between the effects of the two diagnoses (R=0.82, p<2e-16). Data points are labeled with official gene symbols for individual*

*genes with particularly large Log2FC for both diagnoses. **B.** A table of correlation coefficients illustrating the similarity between the differential expression (Log2FC) associated with BP and SCHIZ in BA10 in our qPCR study and the differential expression (Log2FC) associated with both BP and SCHIZ in BA10 as measured by microarray (re-analyzed by our laboratory: (12,13)) and in the DLPFC/frontal cortex as indicated by a meta-analysis of RNA-Seq studies (18), or by microarray (19,20). Bold text indicates significance (p<0.05). **C-D.** Scatterplots illustrating the cross-diagnosis correlation between the effects of BP and SCHIZ within our qPCR dataset (Log2FC) and the effects of BP and SCHIZ within the results from a large RNA-Seq meta-analysis from neighboring cortex (Log2FC, (18)) for all genes that were present in both datasets (95 genes). The color of the datapoints signifies whether a gene showed a nominally significant effect of diagnosis in the RNA-Seq meta-analysis results (black: p<0.05, grey: p>0.05). These findings indicate that the similarity between the effects of BP and SCHIZ within our qPCR dataset is not just an artifact due to using the same CTRL group as reference in our analysis, but a valid property of the diagnosis-related differential expression.*

Exploratory Analyses: Factors Contributing to Diagnosis-Related Gene Expression

To further explore the function of our top diagnosis-related genes (n=20, **Fig 3**), we examined the relationship between gene expression in our qPCR dataset and a rich database of clinical characteristics compiled via in-depth psychological autopsy (**Appendix 1**). Information from coroner records, medical records, and interviews with next-of-kin was summarized as 49 variables (**Fig S6**) denoting the presence or absence of 1) medication, 2) exposure to alcohol or drugs of abuse, and 3) diagnosis-related symptoms. We then evaluated the effect of these variables on gene expression while controlling for diagnosis and relevant biological and technical covariates. Exploratory results with independent validation or support are highlighted below (*details in Supplement*).

Overlap Between the Effects of Diagnosis and Common Therapeutics:
One question that typically arises while interpreting diagnosis effects within human post-mortem studies is whether the observed effects are due to the illness itself or its treatment. Indeed, there were a large number of documented effects (FDR<0.05) of therapeutics on the expression of our top 20 diagnosis-related genes within the comprehensive Drug Gene Budger database (https://maayanlab.cloud/DGB/, (22)), including 169 effects of antipsychotics and 28 effects of antidepressants from a variety of experiments. Given this precedent, we explored the effect of exposure to therapeutics in our qPCR dataset while controlling for diagnosis. Although our analyses were underpowered (*antipsychotics:* n=9; *antidepressants:* n=8), we observed some suggestive results that were bolstered by previous evidence (**Fig S18**). MAOB was down-regulated with antidepressants (Log2FC=-0.457, p=5.25E-06, FDR=0.0562), paralleling previously documented functional inhibition (23,24). We also saw a nominal (p<0.05) downregulation of GPHN with antidepressants, and upregulation of COMT and BDNF with antipsychotics that mirrored the effects in Drug Gene Budger. SST showed a trend (p=0.0728) towards upregulation with antipsychotics that mirrored the effects in Drug Gene Budger and the primate DLPFC (25). Notably, all of these therapeutic effects were in the opposite direction of diagnosis effects in BA10 (**Fig S18**). In contrast, the diagnosis-related increase in SNCA could be an artifact of therapeutics, as we found nominal (p<0.05) upregulation with antidepressants, and substantial previously documented upregulation with both antidepressants and antipsychotics (19 effects: Drug Gene Budger, (25)).

Overlap Between the Effects of Diagnosis and Substances of Abuse:

Similar to many psychiatric studies, our diagnosis groups contained an elevated rate of documented dependence on alcohol and tobacco as well as use of other substances of abuse around the time of death (cannabinoids, opioids, stimulants, **Fig S20**), whether due to therapeutic use, recreation or a substance use disorder. These elevated rates in psychiatric subjects could partially reflect better documentation, as toxicology analysis was often performed following suicide, but they are further supported by the high rate of overdose in the diagnosis groups (SCHIZ: 23%, BP: 52%).

Therefore, we explored whether diagnosis effects in our qPCR dataset could be better explained by substance use. For our top 20 diagnosis-related genes we examined the effect of recent exposure to substances of abuse while controlling for diagnosis. We found that the effects (Log2FC) were surprisingly consistent across substance categories (median: R=0.77, range: R=-0.06-0.88, **Fig S20**), in a manner that exceeded the correlated use of those substances (median: R=0.44, range: R=0.068-0.52, **Fig S20**), suggesting that the results might broadly reflect use behaviors. This was further supported by the similarity between our results and previously documented effects of Opioid Use Disorder (RNA-Seq (26): R=0.26-0.79, median R=0.58, **Fig 5, Fig S20**) and Alcohol Abuse Disorder in the cortex (microarray meta-analysis (18) & RNA-Seq (27): R=-0.03-0.69, median R=0.36, **Fig S20**), but we did not see a similar parallel with the effects of substance use in the smaller Iwamoto BA10 microarray dataset (**Fig S20**, smoking, heavy alcohol, heavy drug use).

A. Opioid Use Effects (Log2FC): Replication

C. Opioid Use amplifies diagnosis-related dysregulation

B. The effects of Opioid Use (Log2FC) resemble the effects of SCHIZ and BP

Figure 5. Exploratory: Substances of abuse may be associated with similar dysregulation of neurotransmission-related gene expression in BA10 as SCHIZ and BP. *Within a set of exploratory analyses, we estimated the differential expression (Log2FC) in the frontal pole*

*(BA10) in our qPCR dataset associated with a variety of substances of abuse (tobacco, cannabinoids, stimulants, opioids) while controlling for diagnosis. Substance exposure was defined by indication of usage within the subjects' clinical records, family interviews, toxicology reports, and coroners reports. To reduce false discovery due to multiple comparisons, this exploratory analysis was limited to the 20 genes with the most reliable diagnosis effects in BA10 (listed in **Fig 3**). The pattern revealed by our exploratory analysis was surprisingly consistent across substances (**Fig S20**), but the largest effects were observed in association with opioid exposure (n=8 subjects). **A.** Replication: Opioid exposure in our BA10 qPCR dataset was associated with similar differential expression (Log2FC) to what had been observed previously in association with opioid use disorder in the dorsolateral prefrontal cortex using RNA-Seq (26) (n=Log2FC for 15 diagnosis-related genes, Pritzker BA10 qPCR vs. Seney DLPFC RNA-Seq: R=0.79, p=0.000499). **B.** Relationship with diagnosis: In general, the effects of diagnosis on gene expression (Log2FC) in BA10 measured in our qPCR study correlated positively with the effects of a variety of substances of abuse (Log2FC; tobacco, cannabinoids, stimulants, opioids) as estimated while controlling for diagnosis in our dataset. The top scatterplot uses Opioid exposure as an example to illustrate the similarity between the effects associated with opioids and diagnosis (x-axis: Blue=Bipolar Disorder Log2FC, Green=Schizophrenia Log2FC, n=Log2FC for 20 diagnosis-related genes, Opioid Log2FC vs.: BP: R=0.90, p=5.04e-08, SCHIZ: R=0.91, p=2.21e-08). The bottom scatterplot shows that the similarity between the effects of opioid use and diagnosis replicates when using the effects of opioid use disorder measured in the previously published Seney et al. (26) dataset (n=Log2FC for 15 diagnosis-related genes, Opioid Use Disorder Log2FC vs.: BP: R=0.89, p=6.43e-06, SCHIZ: R=0.76, p=0.000678). **C.** Opioid use appears to amplify diagnosis-related dysregulation: Example boxplots illustrate the effect of opioid exposure within our diagnosis groups for top diagnosis-related genes (DRD4: effect of Diagnosis (p=0.0190), effect of Opioids (p=0.000208); HTR2B: effect of Diagnosis (p=9.94e-05), effect of Opioids (p=9.42e-09); SST: effect of Diagnosis (p=0.0111), effect of Opioids (p=0.000146)). Plotting conventions follow **Fig 1**, with "yes" and "no" indicating exposure to opioids. Differential expression results for other genes and substances of abuse can be found in **Fig S21**.*

For several genes, the effects of substance use were particularly large and consistent with other evidence. GFAP was upregulated with substance use (FDR<0.10, Log2FC=0.60-0.79: tobacco, simulants, opioids, overdose) in a manner resembling Alcohol Abuse Disorder (18,27). HTR2B was down-regulated with opioid use and overdose (**Fig 5, Fig S21,** FDR<0.10, Log2FC=-1.73,-0.68), in a manner resembling Alcohol Abuse Disorder ((18), but not (27)) and heavy drug use (*Iwamoto*: p<0.09*trend*, Log2FC=-0.18). SST and BDNF were also down-regulated with opioid use (**Fig 5,** FDR<0.10, Log2FC=-0.70,0.71) and overdose (SST: FDR<0.10, Log2FC=-0.60) in a manner resembling opioid use disorder (26). MAPK1 and GABRB1 were upregulated with stimulant use (FDR<0.10, Log2FC=0.15, 0.19) in a manner that resembled opioid use disorder (26) and alcohol abuse disorder (27). We also observed downregulation of DRD4 and SLC6A12 and upregulation of SLC6A11 with substance use (FDR<0.10, **Fig 5, Fig S21**) but lacked independent validation.

Notably, the effects of substance use broadly resembled the effects of diagnosis (**Fig 5, Fig S21,** all relationships R=0.54-0.90, p<0.015), but the diagnosis effects typically persisted after controlling for substance use (**Fig 5, Fig S22**). These exploratory findings are provocative, suggesting a mechanism by which substance use might converge with diagnosis-related dysregulation in frontal cortical function, but require further independent validation.

Overlap Between the Effects of Diagnosis and Symptom Profiles:
In general, there were very few symptoms that had significant effects (FDR<0.10) in our dataset that resembled what we had observed for diagnosis. Surprisingly, the few relationships

that we did observe that resembled the effects of diagnosis were often with symptoms broadly related to executive dysfunction: "agitated" (SNCA, MAPK1, SLC6A12, HTR2B), "interactions with legal system" (GABRB1), "reckless" (NSF), "fatigue" (BDNF), and "trouble concentrating" (GPHN) (**Fig S19**). These results are provocative, especially since some of these genes are also differentially expressed in the cortex in other diagnoses (**Fig S19**) or in response to stress hormones (**Fig S19**), but since the exploratory analyses were run while controlling for diagnosis, we may have had limited power to detect relationships with symptoms that more canonically define BP and SCHIZ, such as psychosis and disturbed affect. Further validation is strongly recommended.

Discussion

Using the highly sensitive method of qPCR, we identified a large downregulation in BP and SCHIZ of two important therapeutic targets with low-levels of expression in BA10, HTR2B and DRD4, and detected weaker downregulation of DRD2 and DRD3. Our qPCR study also highlighted the differential expression of genes related to signaling via GABA and Glutamate, including SST, ABAT, GPHN, and MAPK1. To bolster our findings, we performed a meta-analysis of publicly-released BA10 microarray data (12,13), and identified sources of convergence with our qPCR results. We then compared our BA10 differential expression results to previous transcriptional profiling experiments in neighboring cortex (18–20) and found many similar effects. Using these converging sources of evidence, we identified 20 neurotransmission-related genes that were differentially expressed in BP and SCHIZ in BA10.

This differential expression was often similar across diagnoses, suggesting that gene expression associated with BP and SCHIZ in BA10 may reflect symptoms, risk factors, or experiences common across the two disorders. To explore the factors contributing to diagnosis-related differential expression, we leveraged the unusually large database of clinical metadata associated with our qPCR samples to explore the relationship between BA10 gene expression, therapeutics, substances of abuse, and symptom profiles, and validated these exploratory findings with publicly-available datasets. We found evidence that therapeutics may produce differential expression that often opposes the effects of diagnosis. We also observed that substances of abuse may be associated with similar effects on gene expression in the frontal cortex as BP and SCHIZ, potentially amplifying diagnosis-related dysregulation.

Downregulation of serotonin receptor HTR2B in BP and SCHIZ
The largest effect we observed in our study was a surprisingly strong downregulation of the serotonin receptor HTR2B. Subjects with BP and SCHIZ had almost half as much HTR2B mRNA in BA10 as control subjects. Based on relative prevalence within previous anatomical and cell culture studies, we infer that this expression is probably located in vasculature and microglia (28–30). If so, downregulation may impact two key features of SCHIZ observed in the frontal lobe: decreased vascular flow and aberrant grey matter pruning.

SCHIZ symptoms correlate with decreased regional blood flow in prefrontal areas, including BA10 (31), a feature known as hypofrontality (32,33). HTR2B is expressed in endothelial cells of the cerebral vasculature (30,34) and regulates cerebral blood flow via the release of nitric oxide (28,35). We hypothesize that the downregulation of HTR2B could contribute to hypofrontality in SCHIZ.

During adolescence and early adulthood, the frontal cortex experiences intense pruning that reduces grey matter volume (36,37). This period coincides with the onset of BP and SCHIZ (38). Functional studies have shown that this developmental decrease in BA10 grey matter density is thwarted in SCHIZ (6,39). Since microglia actively engulf synaptic structures during postnatal development, microglial dysfunction may contribute to disorders with aberrant pruning,

including SCHIZ (40). Pure microglial cultures express HTR2B (29), and in the brain, a lack of HTR2B receptors affects microglial activation states and impedes their ability to mediate proper synaptic refinement (41). These findings suggest that a deficit in HTR2B activity could affect microglial function producing defective grey matter pruning in SCHIZ. Conversely, a diagnosis-related decrease in microglia could also produce an overall decrease in HTR2B expression.

This theory assumes that deficits in HTR2B are present during development and play a causal role in disorder onset. There is some support for this assertion: previous exome sequencing studies have identified genetic variants associated with SCHIZ within the HTR2B gene that are predicted to be missense/damaging or stop-gained (42,43). HTR2B knock-out mice also exhibit an antipsychotic-sensitive behavioral phenotype reminiscent of SCHIZ, including decreased pre-pulse inhibition, dysfunctional social interaction, memory and attentional deficits (44). Acute exposure to the HTR2B antagonist RS127445 can produce similar deficits (44).

Within our exploratory results, we also observed decreased HTR2B expression in association with substances of abuse, especially opioids, and the symptom of agitation. These exploratory findings are intriguing, since stop-gained genetic variants within the HTR2B gene are associated with impulsive behavior, including impulsive aggression, especially under the influence of alcohol (43,45). HTR2B knock-out mice are also more impulsive and responsive to novelty (43), and show greater amphetamine-evoked hyperactivity (44). Paradoxically, HTR2B antagonists can suppress the hyperactivity elicited by many drugs of abuse and interfere with conditioned place preference (46). Collectively, these findings lend plausibility to the idea that deficits in HTR2B could affect impulsivity and drug-taking behavior, offering one explanation for the common covariation of substance use with BP and SCHIZ.

Dopaminergic Gene Expression in BP and SCHIZ

The availability of dopamine is pivotal to frontal cortex function, and both decreased and increased availability disturb proper functioning (47–49). Disturbed dopamine function in the frontal cortex is considered an important feature in psychotic disorders, as most antipsychotic treatments target DRD2-like dopamine receptors (DRD2, DRD3, DRD4) (11). These dopamine receptors are located near genetic risk loci for SCHIZ (genome wide association (DRD2): (50); linkage and association studies (DRD2, DRD3, DRD4): (51–54)), and contain risk variants predicted to be missense/damaging or stop-gained (DRD2 (55), DRD3 (42)), implying that deficits in dopamine function may contribute to the disorder.

However, the relationship between psychotic disorders and the expression of DRD2-like dopamine receptors has been previously difficult to characterize, as these receptors have low levels of expression in the frontal cortex (11,56). Early attempts using PCR to measure DRD2-like dopamine receptor expression in the frontal cortex, including BA10, produced mixed results (57–59), although notably an *in situ* hybridization study from our lab detected region-specific, large-magnitude decreases in DRD4 and DRD3 in SCHIZ in the nearby BA11 region (60). Using more modern qPCR methods, DRD2 was found to be decreased with SCHIZ and increased with BP in the neighboring DLPFC (11). In our study, we show that current qPCR methodology can reliably measure very low levels of expression, including the expression of DRD2-like dopamine receptors. Using this methodology, we discovered surprisingly large effect sizes that dwarf those previously measured with less sensitive methodology (microarray, RNA-Seq).

Out of all of the dopamine receptors, DRD4 showed the largest decrease in BP and SCHIZ. A decrease in DRD4 receptor activity could contribute to diagnosis-related disruptions in excitatory/inhibitory balance. An altered ratio of excitation to inhibition in areas associated with cortical inhibitory control has been hypothesized to be a key feature of psychiatric illnesses with severe social and cognitive deficits (61,62). DRD4 agonists and antagonists decrease and increase postsynaptic GABA(A) receptor currents, respectively (63), and decreased DRD4 responsiveness is associated with decreased hemodynamic activity in cortical areas (64). More

importantly, DRD4 knockout mice show disrupted GABAergic activity, which facilitates the development of SCHIZ-like symptoms under stress (65). Moreover, the atypical antipsychotic clozapine has a high affinity for DRD4, and DRD4 knock-out mice are less responsive to its behavioral effects (66), suggesting that a decrease in DRD4 in BP and SCHIZ could be relevant not only to the manifestation of the disorders but also hinder successful treatment.

During our exploratory analyses, we also observed a decrease in DRD4 in association with substance use but were unable to find validation in an independent dataset. That said, DRD4 knock-out mice show enhanced locomotor hyperactivity in response to ethanol, cocaine, and methamphetamine (66), and polymorphisms in the DRD4 gene have been implicated in substance use and attention deficit hyperactivity disorder (67). Therefore, similar to HTR2B, a decrease in DRD4 might promote the common covariation of substance use with BP and SCHIZ.

The enzyme catechol-O-methyltransferase (COMT) has been previously theorized to play a role in psychiatric disorders (48,68–70). Termination of monoamine activity in the frontal cortex depends mostly on the activity of COMT instead of being cleared by the dopamine transporter as is the case in other brain regions (71). COMT is located within a risk locus for SCHIZ implicated by copy number variation (72) and by meta-analyses of linkage (53,54) and association studies (51,52). We observed a nominal decrease in COMT in both of the BA10 microarray datasets that we reanalyzed. This downregulation might increase dopamine levels (48), with behavioral consequences such as aggression and increased sensitivity to stress (71). We did not observe a similar diagnosis effect in our qPCR dataset, but did see evidence that COMT might be upregulated by antipsychotic medication in a manner paralleling what had been observed in cell culture and other tissues (22).

GABA-related Gene Expression in BP and SCHIZ

Previous studies in neighboring frontal cortex areas have repeatedly shown large decreases in somatostatin (SST) in BP and SCHIZ ((18,21,73,74), review: (75)) but to our knowledge our study is the first to show a significant decrease in BA10. Somatostatin is selectively expressed in a subset of GABA-ergic interneurons which represent ~30% of the total cortical interneuron population (76). SST neurons synapse on pyramidal cell dendritic shafts and spines, indicating a role in filtering excitatory glutamatergic inputs (77). A reduction in SST interneuron function in SCHIZ is theorized to contribute to disruptions in cortical information integration processes, such as working memory (75). That said, decreased SST is not specific to psychotic disorders, and has been observed in Major Depressive Disorder ((33), e.g. **Fig S18**) and following chronic stress in animals (78). SST plays an important role in anxiety: SST neurons in the frontal cortex modulate anxiety-like behaviors and SST knock-out mice display elevated anxiety and corticosterone levels (78). Both post-mortem and preclinical studies also link SST to drug-taking behavior (26,78), which supports the association between substance use and decreased SST that we observed in our exploratory analyses. Altogether, SST appears to be a compelling convergence point for stress to aggravate a variety of psychiatric symptoms.

Both BP and SCHIZ also exhibited increased Gephryin (GPHN), a postsynaptic scaffolding protein which is abundant in the human cortex and localized to cell bodies and the apical dendrites of pyramidal neurons (79). GPHN helps cluster, anchor, and stabilize GABA(A) and glycine receptors at inhibitory synapses (80). Therefore, the upregulation of GPHN in BP and SCHIZ could be related to the shift in GABA(A) receptor subunit composition that occurs at postsynaptic sites (81,82), potentially contributing to increased GABA(A) receptor binding in the frontal cortex in SCHIZ (82,83). This change in GABA(A) receptor binding, as well as the increased GABRB1 receptor subunit expression that we observed in SCHIZ, might serve as a compensatory mechanism for disturbed local GABAergic neurotransmission.

Astrocyte-related Gene Expression in BP and SCHIZ

One of the largest effects in our dataset was an upregulation of GFAP in SCHIZ, an effect previously observed in neighboring frontal cortex (18). Increased expression of the intermediate filament GFAP is a hallmark of astrocyte activation (84,85) and follows increased intracellular calcium signaling (86). Astrocyte reactivity is found in many pathological states involving excitotoxicity (84,85), but we found little evidence of diagnosis-related glutamatergic alterations in BA10, with the exception of nominal elevations of glutamate metabotropic receptor 5 (GRM5). Instead, we hypothesize that astrocyte activation elicited by GABAergic stimulation might be a feature of BP and SCHIZ.

In general, GABA is considered an inhibitory neurotransmitter, but in astrocytes it can elicit regional excitation of the glial syncytium. GABAergic interneuron activity results in intracellular calcium increases in surrounding astrocytes (87) in a manner that is dependent on GABA transporters (88). Activation of GABA(A) or GABA(B) receptors on astrocytes elevates cytosolic calcium levels (89,90). Therefore, our results showing increased GABRB1 receptor subunit expression in SCHIZ could suggest a mechanism for increased astrocyte activation.

We also found increased expression of MAOB in both disorders. The main function of this enzyme is to synthesize GABA in astrocytes, which is then released, causing extra-synaptic tonic inhibition (91). Reactive astrocytes that exhibit increased GFAP expression produce excess GABA release, increasing tonic inhibition and affecting dopamine function, an effect reversed by blocking MAOB activity (92). Our results suggest a similar effect, accentuated by the overexpression of GABA(B) receptors, the activation of which inhibits dopamine release (93,94). Therefore, we believe that astrocyte reactivity in BP and SCHIZ could be another contributing factor to dopaminergic dysfunction by way of a disruption of the glial GABAergic system.

In contrast, we saw a nominal decrease in the expression of the GABA transporter GAT-3 with SCHIZ, which is encoded by the SLC6A11 gene. SLC6A11 is abundantly expressed in astrocyte processes surrounding synapses and neuronal bodies (95,96). GAT-3 activity results in sodium ion accumulation by astrocytes, with a consequent increase in intracellular calcium via sodium/calcium exchange. Therefore, a decrease in GAT-3 function could partially compensate for elevations in calcium due to increased GABA signaling.

Finally, astrocytic metabolism of GABA is performed by the mitochondrial GABA transaminase, encoded by the ABAT gene (97). We found ABAT to be upregulated in BP and SCHIZ. Increased expression of this degrading enzyme could shorten the availability of GABA, causing a disinhibitory effect. Increased ABAT expression could underlie manic symptoms in BP and SCHIZ, as ABAT deficiency has been associated with inconsolable crying, dullness, and lethargy (98) and increased ABAT expression has been associated with aggression in a preclinical model (99).

Interestingly, signatures of glial activation (upregulation of GFAP) and GABA dysfunction (upregulation of SLC6A11 and GABRB1) were also strongly associated with substance use in our exploratory analyses, as well as the symptoms "interactions with the legal system" (GABRB1) and "fatigue" (SLC6A11). This raises the question as to whether glial activation and GABA dysfunction in BA10 might be particularly important for the executive dysfunction and cognitive symptoms that accompany BP and SCHIZ. This could complement recent evidence showing elevated serum levels of GFAP in association with declines in executive function, memory and attention in older individuals (100).

Conclusion

In conclusion, SCHIZ and BP are associated with a notable dysregulation of neurotransmission-related gene expression in BA10, a cortical area highly specialized in humans. These effects included alterations in gene expression underlying serotonin, dopamine, GABA, and astrocytic networks. We hypothesize that these disruptions underlie specific cognitive and behavioral manifestations common to the two disorders.

Methods

This research was overseen and approved by the University of Michigan Institutional Review Board, Pritzker Neuropsychiatric Disorders Research Consortium, and the University of California Irvine Institutional Review Board. An overview of the experimental design can be found in **Fig S1**. Full methodological details are documented in the supplement.

Human samples and clinical data were collected through the Brain Donor Program at the University of California-Irvine with informed consent from next of kin (n=72, CTRL: *n*=27, BPD: *n*=21, SCHIZ: *n*=24; **Table S1, Fig S2** (101)). Diagnostic criteria for BP and SCHIZ came from the Diagnostics and Statistical Manual of Mental Disorders (8). There was no evidence of neurological or psychiatric disorder in CTRL subjects or their first-degree relatives. Brains were extracted during autopsy and kept on ice until being sliced into 1 cm thick coronal slabs, snap-frozen, and stored at -80 ℃ until microdissection.

Within batches counterbalanced by diagnosis, the foremost rostral slab was sub-dissected to obtain blocks averaging 500 µg that contained BA10 (**Fig S3**). RNA extraction was then extracted using TRIzol™ (ThermoFisher Scientific Cat#15596026/15596018), and purified with the RNeasy® Mini Kit (Qiagen Cat#74106). cDNA was synthesized using iScript Reverse Transcription Supermix kit (Bio-Rad REF#1708841). cDNA samples were then analyzed in duplicate via qPCR performed using the Applied Biosystems ViiA 7 real time PCR system and two sets of Taqman Gene Expression Custom Array qPCR cards: 1) Human GABA Glutamate (ThermoFisher Scientific REF#4342259): 84 targets (12 reference genes), 2) Dopamine Serotonin (ThermoFisher Scientific REF#4342253): 31 targets (17 reference genes) (**Table S2**). The full qPCR datasets (Cq) and normalized results (-ΔCq) have been released on FigShare (*link TBA*), along with all de-identifiable metadata (64 technical and clinical variables).

For comparison, we performed a meta-analysis of publicly-released BA10 microarray data (re-annotated and re-analyzed: Gene Expression Omnibus #GSE12654 (12): *n*=50, CTRL: n=15, BPD: n=11, SCHIZ: n=13, MDD=11; #GSE17612 (13): *n*=51, CTRL: n=23, SCHIZ: n=28) using random effects modeling (102) of the Log2FC and sampling variance (SE^2) for each gene (EntrezID) from the *limma* (103) differential expression output for each dataset.

Both qPCR and microarray differential expression analyses controlled for common sources of biological and technical noise (*all:* pH, PMI, age, gender; *qPCR:* RIN, RNA concentration, Card; *microarray* (when applicable): RNA degradation, Rate of Death, Scan Date) and corrected for false discovery rate (FDR: Benjamini-Hochberg method (104)). All analysis code (Rstudio v1.0.153, R v3.4.1) has been released on Github (*link TBA*).

Acknowledgements

We thank Jennifer Fitzpatrick and Linda Morgan for their expert technical assistance on the project, and Richard Stein, Ph.D. for his work overseeing the clinical metadata database.

This work was primarily supported by the Pritzker Neuropsychiatric Disorders Research Consortium [to HA and SJW]. This work was further supported by grants from the Hope for Depression Research Foundation (RGA No. DTF Phase II [D]), National Institute on Drug Abuse (Grant #U01-DA043098 [to HA]), Office of Naval Research (Grant # 00014-19-1-2149 [to HA]), and National Institute of Mental Health (Grant # R01-MH-08580 [to MPV]). Research training for LTF and ER was supported by the Undergraduate Research Opportunity Program at the University of Michigan.

All authors are members of the Pritzker Neuropsychiatric Disorders Research Consortium, which is supported by Pritzker Neuropsychiatric Disorders Research Fund. A shared intellectual property agreement exists between the academic and philanthropic entities of the consortium. All authors report no biomedical financial interests or potential conflicts of interest.

References

1. Ramnani N, Owen AM (2004): Anterior prefrontal cortex: insights into function from anatomy and neuroimaging [no. 3]. *Nat Rev Neurosci* 5: 184–194.

2. Semendeferi K, Armstrong E, Schleicher A, Zilles K, Van Hoesen GW (2001): Prefrontal cortex in humans and apes: A comparative study of area 10 [no. 3]. *Am J Phys Anthropol* 114: 224–241.

3. Donahue CJ, Glasser MF, Preuss TM, Rilling JK, Van Essen DC (2018): Quantitative assessment of prefrontal cortex in humans relative to nonhuman primates [no. 22]. *Proc Natl Acad Sci USA* 115: E5183–E5192.

4. Semendeferi K, Teffer K, Buxhoeveden DP, Park MS, Bludau S, Amunts K, *et al.* (2011): Spatial organization of neurons in the frontal pole sets humans apart from great apes [no. 7]. *Cereb Cortex* 21: 1485–1497.

5. Petrides M, Pandya DN (1999): Dorsolateral prefrontal cortex: comparative cytoarchitectonic analysis in the human and the macaque brain and corticocortical connection patterns: Dorsolateral prefrontal cortex in human and monkey [no. 3]. *European Journal of Neuroscience* 11: 1011–1036.

6. John JP, Burgess PW, Yashavantha BS, Shakeel MK, Halahalli HN, Jain S (2009): Differential relationship of frontal pole and whole brain volumetric measures with age in neuroleptic-naïve schizophrenia and healthy subjects. *Schizophrenia Research* 109: 148–158.

7. Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, *et al.* (2016): Gene expression elucidates functional impact of polygenic risk for schizophrenia. *Nat Neurosci* 19: 1442–1453.

8. American Psychiatric Association, American Psychiatric Association (Eds.) (2013): *Diagnostic and Statistical Manual of Mental Disorders: DSM-5*, 5th ed. Washington, D.C: American Psychiatric Association.

9. Pietraszek M (2003): Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms. *Pol J Pharmacol* 55: 133–154.

10. Selvaraj S, Arnone D, Cappai A, Howes O (2014): Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. *Neurosci Biobehav Rev* 45: 233–245.

11. Zhan L, Kerr JR, Lafuente M-J, Maclean A, Chibalina MV, Liu B, *et al.* (2011): Altered expression and coregulation of dopamine signalling genes in schizophrenia and bipolar disorder. *Neuropathol Appl Neurobiol* 37: 206–219.

12. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T (2004): Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. *Mol Psychiatry* 9: 406–416.

13. Maycox PR, Kelly F, Taylor A, Bates S, Reid J, Logendra R, *et al.* (2009): Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. *Mol Psychiatry* 14: 1083–1094.

14. Ohayon S, Yitzhaky A, Hertzberg L (2020): Gene expression meta-analysis reveals the up-regulation of CREB1 and CREBBP in Brodmann Area 10 of patients with schizophrenia. *Psychiatry Res* 292: 113311.

15. Scarr E, Udawela M, Dean B (2018): Changed frontal pole gene expression suggest altered interplay between neurotransmitter, developmental, and inflammatory pathways in schizophrenia. *NPJ Schizophr* 4: 4.

16. Scarr E, Udawela M, Dean B (2019): Changed cortical risk gene expression in major depression and shared changes in cortical gene expression between major depression and bipolar disorders. *Aust N Z J Psychiatry* 53: 1189–1198.

17. Purves D, Augustine GJ, Fitzpatrick D, Katz LC, LaMantia A-S, McNamara JO, Williams SM (2001): *Neuroscience*, 2nd ed. Sinauer Associates.

18. Gandal MJ, Haney JR, Parikshak NN, Leppa V, Ramaswami G, Hartl C, *et al.* (2018): Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. *Science* 359: 693–697.

19. Lanz TA, Reinhart V, Sheehan MJ, Rizzo SJS, Bove SE, James LC, *et al.* (2019): Postmortem transcriptional profiling reveals widespread increase in inflammation in schizophrenia: a comparison of prefrontal cortex, striatum, and hippocampus among matched tetrads of controls with subjects diagnosed with schizophrenia, bipolar or major depressive disorder. *Transl Psychiatry* 9: 151.

20. Narayan S, Tang B, Head SR, Gilmartin TJ, Sutcliffe JG, Dean B, Thomas EA (2008): Molecular profiles of schizophrenia in the CNS at different stages of illness. *Brain Res* 1239: 235–248.

21. Hagenauer MH, Schulmann A, Li JZ, Vawter MP, Walsh DM, Thompson RC, *et al.* (2018): Inference of cell type content from human brain transcriptomic datasets illuminates the effects of age, manner of death, dissection, and psychiatric diagnosis. *PLoS ONE* 13: e0200003.

22. Wang Z, He E, Sani K, Jagodnik KM, Silverstein MC, Ma'ayan A (2019): Drug Gene Budger (DGB): an application for ranking drugs to modulate a specific gene based on transcriptomic signatures. *Bioinformatics* 35: 1247–1248.

23. Fisar Z, Hroudová J, Raboch J (2010): Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. *Neuro Endocrinol Lett* 31: 645–656.

24. Leonardi ET, Azmitia EC (1994): MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). *Neuropsychopharmacology* 10: 231–238.

25. Martin MV, Mirnics K, Nisenbaum LK, Vawter MP (2015): Olanzapine Reversed Brain Gene Expression Changes Induced by Phencyclidine Treatment in Non-Human Primates. *Mol Neuropsychiatry* 1: 82–93.

26. Seney ML, Kim S-M, Glausier JR, Hildebrand MA, Xue X, Zong W, *et al.* (2021): Transcriptional Alterations in Dorsolateral Prefrontal Cortex and Nucleus Accumbens Implicate Neuroinflammation and Synaptic Remodeling in Opioid Use Disorder. *Biol Psychiatry* 90: 550–562.

27. Kapoor M, Wang J-C, Farris SP, Liu Y, McClintick J, Gupta I, *et al.* (2019): Analysis of whole genome-transcriptomic organization in brain to identify genes associated with alcoholism. *Transl Psychiatry* 9: 89.

28. Schmuck K, Ullmer C, Kalkman HO, Probst A, Lubbert H (1996): Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? *Eur J Neurosci* 8: 959–967.

29. Krabbe G, Matyash V, Pannasch U, Mamer L, Boddeke HWGM, Kettenmann H (2012): Activation of serotonin receptors promotes microglial injury-induced motility but attenuates phagocytic activity. *Brain, Behavior, and Immunity* 26: 419–428.

30. Ullmer C, Schmuck K, Kalkman HO, Lübbert H (1995): Expression of serotonin receptor mRNAs in blood vessels [no. 3]. *FEBS Letters* 370: 215–221.

31. Liddle PF, Friston KJ, Frith CD, Frackowiak RS (1992): Cerebral blood flow and mental processes in schizophrenia. *J R Soc Med* 85: 224–227.

32. Kurachi M, Kobayashi K, Matsubara R, Hiramatsu H, Yamaguchi N, Matsuda H, *et al.* (1985): Regional cerebral blood flow in schizophrenic disorders. *Eur Neurol* 24: 176–181.

33. Pratt JA, Winchester C, Egerton A, Cochran SM, Morris BJ (2008): Modelling prefrontal cortex deficits in schizophrenia: implications for treatment: Modelling prefrontal cortex deficits in schizophrenia [no. S1]. *British Journal of Pharmacology* 153: S465–S470.

34. Leysen JE (2004): 5-HT2 Receptors. *Current Drug Targets - CNS & Neurological Disorders* 3: 11–26.

35. Paolucci M, Altamura C, Vernieri F (2021): The Role of Endothelial Dysfunction in the Pathophysiology and Cerebrovascular Effects of Migraine: A Narrative Review [no. 2]. *J Clin Neurol* 17: 164–175.

36. Huttenlocher PR (1979): Synaptic density in human frontal cortex - developmental changes and effects of aging [no. 2]. *Brain Res* 163: 195–205.

37. Dumontheil I, Burgess PW, Blakemore S-J (2008): Development of rostral prefrontal cortex and cognitive and behavioural disorders. *Developmental Medicine & Child Neurology* 50: 168–181.

38. Gogtay N, Vyas NS, Testa R, Wood SJ, Pantelis C (2011): Age of Onset of Schizophrenia: Perspectives From Structural Neuroimaging Studies. *Schizophrenia Bulletin* 37: 504–513.

39. Goldstein JM (1999): Cortical Abnormalities in Schizophrenia Identified by Structural Magnetic Resonance Imaging. *Archives of General Psychiatry* 56: 537–547.

40. Kettenmann H, Kirchhoff F, Verkhratsky A (2013): Microglia: new roles for the synaptic stripper. *Neuron* 77: 10–18.

41. Kolodziejczak M, Béchade C, Gervasi N, Irinopoulou T, Banas SM, Cordier C, *et al.* (2015): Serotonin Modulates Developmental Microglia via 5-HT $_{2B}$ Receptors: Potential Implication during Synaptic Refinement of Retinogeniculate Projections [no. 7]. *ACS Chem Neurosci* 6: 1219–1230.

42. Genovese G, Fromer M, Stahl EA, Ruderfer DM, Chambert K, Landén M, *et al.* (2016): Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. *Nat Neurosci* 19: 1433–1441.

43. Bevilacqua L, Doly S, Kaprio J, Yuan Q, Tikkanen R, Paunio T, *et al.* (2010): A population-specific HTR2B stop codon predisposes to severe impulsivity. *Nature* 468: 1061–1066.

44. Pitychoutis PM, Belmer A, Moutkine I, Adrien J, Maroteaux L (2015): Mice Lacking the Serotonin Htr2B Receptor Gene Present an Antipsychotic-Sensitive Schizophrenic-Like Phenotype. *Neuropsychopharmacology* 40: 2764–2773.

45. Tikkanen R, Tiihonen J, Rautiainen MR, Paunio T, Bevilacqua L, Panarsky R, *et al.* (2015): Impulsive alcohol-related risk-behavior and emotional dysregulation among individuals with a serotonin 2B receptor stop codon. *Transl Psychiatry* 5: e681.

46. Devroye C, Cathala A, Piazza PV, Spampinato U (2018): The central serotonin2B receptor as a new pharmacological target for the treatment of dopamine-related neuropsychiatric disorders: Rationale and current status of research. *Pharmacol Ther* 181: 143–155.

47. Seamans JK, Yang CR (2004): The principal features and mechanisms of dopamine modulation in the prefrontal cortex [no. 1]. *Progress in Neurobiology* 74: 1–58.

48. Tunbridge EM, Harrison PJ, Weinberger DR (2006): Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond. *Biological Psychiatry* 60: 141–151.

49. Diamond A (2007): Consequences of Variations in Genes that affect Dopamine in Prefrontal Cortex. *Cerebral Cortex* 17: i161–i170.

50. Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, *et al.* (2018): Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat Genet* 50: 381–389.

51. Allen NC, Bagade S, McQueen MB, Ioannidis JPA, Kavvoura FK, Khoury MJ, *et al.* (2008): Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. *Nat Genet* 40: 827–834.

52. Sun J, Kuo P-H, Riley BP, Kendler KS, Zhao Z (2008): Candidate genes for schizophrenia: a survey of association studies and gene ranking. *Am J Med Genet B Neuropsychiatr Genet* 147B: 1173–1181.

53. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, *et al.* (2003): Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. *Am J Hum Genet* 73: 34–48.

54. Ng MYM, Levinson DF, Faraone SV, Suarez BK, DeLisi LE, Arinami T, *et al.* (2009): Meta-analysis of 32 genome-wide linkage studies of schizophrenia. *Mol Psychiatry* 14: 774–785.

55. Howrigan DP, Rose SA, Samocha KE, Fromer M, Cerrato F, Chen WJ, *et al.* (2020): Exome sequencing in schizophrenia-affected parent-offspring trios reveals risk conferred by protein-coding de novo mutations. *Nat Neurosci* 23: 185–193.

56. Rothmond DA, Weickert CS, Webster MJ (2012): Developmental changes in human dopamine neurotransmission: cortical receptors and terminators. *BMC Neurosci* 13: 18.

57. Roberts DA, Balderson D, Pickering-Brown SM, Deakin JF, Owen F (1996): The relative abundance of dopamine D4 receptor mRNA in post mortem brains of schizophrenics and controls. *Schizophr Res* 20: 171–174.

58. Mulcrone J, Kerwin RW (1996): No difference in the expression of the D4 gene in post-mortem frontal cortex from controls and schizophrenics. *Neurosci Lett* 219: 163–166.

59. Stefanis NC, Bresnick JN, Kerwin RW, Schofield WN, McAllister G (1998): Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain. *Brain Res Mol Brain Res* 53: 112–119.

60. Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, Watson SJ (1996): Dopamine receptor mRNA expression in human striatum and neocortex. *Neuropsychopharmacology* 15: 17–29.

61. Yizhar O, Fenno LE, Prigge M, Schneider F, Davidson TJ, O'Shea DJ, *et al.* (2011): Neocortical excitation/inhibition balance in information processing and social dysfunction [no. 7363]. *Nature* 477: 171–178.

62. Mehta UM, Ektare A, Jakhar J, Basavaraju R, Sanjay TN, Naik SS, *et al.* (2021): A transdiagnostic evaluation of cortical inhibition in severe mental disorders using Transcranial Magnetic Stimulation. *Journal of Psychiatric Research* 143: 364–369.

63. Wang X, Zhong P, Yan Z (2002): Dopamine D$_4$ Receptors Modulate GABAergic Signaling in Pyramidal Neurons of Prefrontal Cortex. *J Neurosci* 22: 9185–9193.

64. Mulligan RC, Kristjansson SD, Reiersen AM, Parra AS, Anokhin AP (2014): Neural correlates of inhibitory control and functional genetic variation in the dopamine D4 receptor gene. *Neuropsychologia* 62: 306–318.

65. Tan T, Wang W, Williams J, Ma K, Cao Q, Yan Z (2019): Stress Exposure in Dopamine D4 Receptor Knockout Mice Induces Schizophrenia-Like Behaviors via Disruption of GABAergic Transmission [no. 5]. *Schizophrenia Bulletin* 45: 1012–1023.

66. Rubinstein M, Phillips TJ, Bunzow JR, Falzone TL, Dziewczapolski G, Zhang G, *et al.* (1997): Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. *Cell* 90: 991–1001.

67. Ptáček R, Kuželová H, Stefano GB (2011): Dopamine D4 receptor gene DRD4 and its association with psychiatric disorders. *Med Sci Monit* 17: RA215–RA220.

68. Tunbridge E, Burnet PWJ, Sodhi MS, Harrison PJ (2004): Catechol-o-methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression. *Synapse* 51: 112–118.

69. Walshe M, Vassos E, Picchioni M, Shaikh M, Toulopoulou T, Collier D, *et al.* (2012): The Association between COMT, BDNF, and NRG1 and Premorbid Social Functioning in Patients with Psychosis, Their Relatives, and Controls. *Scientifica* 2012: 1–6.

70. Srivastava K, Ochuba O, Sandhu JK, Alkayyali T, Ruo SW, Waqar A, *et al.* (2021): Effect of Catechol-O-Methyltransferase Genotype Polymorphism on Neurological and Psychiatric Disorders: Progressing Towards Personalized Medicine [no. 9]. *Cureus* 13: e18311.

71. Dauvilliers Y, Tafti M, Landolt HP (2015): Catechol-O-methyltransferase, dopamine, and sleep-wake regulation. *Sleep Medicine Reviews* 22: 47–53.

72. Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, *et al.* (2017): Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat Genet* 49: 27–35.

73. Morris HM, Hashimoto T, Lewis DA (2008): Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. *Cereb Cortex* 18: 1575–1587.

74. Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, Lewis DA (2008): Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. *Am J Psychiatry* 165: 479–489.

75. Van Derveer AB, Bastos G, Ferrell AD, Gallimore CG, Greene ML, Holmes JT, *et al.* (2021): A Role for Somatostatin-Positive Interneurons in Neuro-Oscillatory and Information Processing Deficits in Schizophrenia. *Schizophr Bull* 47: 1385–1398.

76. Rudy B, Fishell G, Lee S, Hjerling-Leffler J (2011): Three groups of interneurons account for nearly 100% of neocortical GABAergic neurons [no. 1]. *Dev Neurobiol* 71: 45–61.

77. Melchitzky DS, Lewis DA (2008): Dendritic-targeting GABA neurons in monkey prefrontal cortex: comparison of somatostatin- and calretinin-immunoreactive axon terminals. *Synapse* 62: 456–465.

78. Robinson SL, Thiele TE (2020): A role for the neuropeptide somatostatin in the neurobiology of behaviors associated with substances abuse and affective disorders. *Neuropharmacology* 167: 107983.

79. Waldvogel HJ, Baer K, Snell RG, During MJ, Faull RLM, Rees MI (2003): Distribution of gephyrin in the human brain: an immunohistochemical analysis. *Neuroscience* 116: 145–156.

80. Choii G, Ko J (2015): Gephyrin: a central GABAergic synapse organizer. *Exp Mol Med* 47: e158.

81. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, Jones EG (1995): Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics [no. 4]. *Arch Gen Psychiatry* 52: 258–266.

82. Verdurand M, Fillman SG, Weickert CS, Zavitsanou K (2013): Increases in [3H]muscimol and [3H]flumazenil binding in the dorsolateral prefrontal cortex in schizophrenia are linked to α4 and γ2S mRNA levels respectively [no. 1]. *PLoS One* 8: e52724.

83. Benes FM, Vincent SL, Todtenkopf M (2001): The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects [no. 6]. *Biol Psychiatry* 50: 395–406.

84. Pekny M, Nilsson M (2005): Astrocyte activation and reactive gliosis. *Glia* 50: 427–434.

85. Pekny M, Wilhelmsson U, Pekna M (2014): The dual role of astrocyte activation and reactive gliosis. *Neuroscience Letters* 565: 30–38.

86. Kanemaru K, Kubota J, Sekiya H, Hirose K, Okubo Y, Iino M (2013): Calcium-dependent N-cadherin up-regulation mediates reactive astrogliosis and neuroprotection after brain injury. *Proc Natl Acad Sci USA* 110: 11612–11617.

87. Kang J, Jiang L, Goldman SA, Nedergaard M (1998): Astrocyte-mediated potentiation of inhibitory synaptic transmission. *Nat Neurosci* 1: 683–692.

88. Deemyad T, Lüthi J, Spruston N (2018): Astrocytes integrate and drive action potential firing in inhibitory subnetworks. *Nat Commun* 9: 4336.

89. Mariotti L, Losi G, Sessolo M, Marcon I, Carmignoto G (2016): The inhibitory neurotransmitter GABA evokes long-lasting C a $^{2+}$ oscillations in cortical astrocytes [no. 3]. *Glia* 64: 363–373.

90. Nilsson M, Eriksson PS, Rönnbäck L, Hansson E (1993): GABA induces Ca2+ transients in astrocytes [no. 3]. *Neuroscience* 54: 605–614.

91. Yoon B, Woo J, Chun Y, Chun H, Jo S, Bae JY, *et al.* (2014): Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition [no. 22]. *J Physiol* 592: 4951–4968.

92. Heo JY, Nam M-H, Yoon HH, Kim J, Hwang YJ, Won W, *et al.* (2020): Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson's Disease. *Current Biology* 30: 276-291.e9.

93. Sulzer D, Cragg SJ, Rice ME (2016): Striatal dopamine neurotransmission: Regulation of release and uptake [no. 3]. *Basal Ganglia* 6: 123–148.

94. Smolders I, De Klippel N, Sarre S, Ebinger G, Michotte Y (1995): Tonic GABA-ergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat [no. 1–2]. *Eur J Pharmacol* 284: 83–91.

95. Boddum K, Jensen TP, Magloire V, Kristiansen U, Rusakov DA, Pavlov I, Walker MC (2016): Astrocytic GABA transporter activity modulates excitatory neurotransmission. *Nat Commun* 7: 13572.

96. Mederos S, Perea G (2019): GABAergic-astrocyte signaling: A refinement of inhibitory brain networks [no. 10]. *Glia* 67: 1842–1851.

97. Besse A, Wu P, Bruni F, Donti T, Graham BH, Craigen WJ, *et al.* (2015): The GABA transaminase, ABAT, is essential for mitochondrial nucleoside metabolism [no. 3]. *Cell Metab* 21: 417–427.

98. Hegde AU, Karnavat PK, Vyas R, DiBacco ML, Grant PE, Pearl PL (2019): GABA Transaminase Deficiency With Survival Into Adulthood [no. 4]. *J Child Neurol* 34: 216–220.

99. Jager A, Amiri H, Bielczyk N, van Heukelum S, Heerschap A, Aschrafi A, *et al.* (2020): Cortical control of aggression: GABA signalling in the anterior cingulate cortex. *European Neuropsychopharmacology* 30: 5–16.

100. Verberk IMW, Laarhuis MB, Bosch KA van den, Ebenau JL, Leeuwenstijn M van, Prins ND, *et al.* (2021): Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. *The Lancet Healthy Longevity* 2: e87–e95.

101. Atz M, Walsh D, Cartagena P, Li J, Evans S, Choudary P, *et al.* (2007): Methodological considerations for gene expression profiling of human brain. *J Neurosci Methods* 163: 295–309.

102. Viechtbauer W (2010): Conducting Meta-Analyses in R with The metafor Package. *Journal of Statistical Software* 36. https://doi.org/10.18637/jss.v036.i03

103. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015): limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 43: e47.

104. Pollard KS, Dudoit S, Laan MJ van der (2005): Multiple Testing Procedures: the multtest Package and Applications to Genomics. *Bioinformatics and Computational Biology Solutions Using R and Bioconductor*. Springer, New York, NY, pp 249–271.